What does this research mean for the field?

The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery and systemic therapy significantly improves overall survival and progression-free survival in patients with colorectal cancer and peritoneal metastases. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the therapeutic efficacy of combining hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery (CRS) and systemic therapy in patients with colorectal cancer and peritoneal metastases.

August 27, 2026

Hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery and systemic therapy improves prognosis in colorectal cancer with peritoneal metastases: an updated meta-analysis.

View Full Paper

Ask AI

Bookmark

Authors

KHK Q HuZhejiang Chinese Medical University XHXuanhao HuUniversity of Science and Technology of China TJTing JiangZhejiang Chinese Medical University

Discussion

Member takes

Implication

Meta-analysis demonstrates improved survival with HIPEC in colorectal cancer with peritoneal metastases, indicating substantial clinical benefits from combined therapy.

Key Points

To evaluate the therapeutic efficacy of combining hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery (CRS) and systemic therapy in patients with colorectal cancer and peritoneal metastases.
Systematic search of PubMed, Web of Science, Embase, and Cochrane Library databases from inception to March 2026.
Synthesized data from 12 studies (2 randomized controlled trials, 9 cohort studies, and 1 case-control study) comprising >2,700 patients to assess progression-free survival (PFS) and overall survival (OS) via pooled hazard ratios (HRs).
HIPEC significantly improved OS (HR = 0.60, 95% CI: 0.51 to 0.70, P < 0.001, I² = 18.2%), representing a 40% reduction in mortality risk.
PFS was significantly prolonged with HIPEC (HR = 0.51, 95% CI: 0.30 to 0.87, P = 0.013, I² = 76.3%), reflecting a 49% reduction in the risk of disease progression or death.
PFS benefits were significant in patients with a peritoneal cancer index (PCI) < 11 (HR = 0.74, P = 0.043) but not PCI ≥ 11 (HR = 0.45, P = 0.066), while OS benefits remained consistent across Eastern (HR = 0.50) and Western (HR = 0.62) cohorts.

Cite This Study

Hu et al. (2026) studied this question.

synapsesocial.com/papers/6a8fe99110c91c1e926213ac https://doi.org/10.1159/ocl/aebag002

View Full Paper

Ask AI

Bookmark

Implication

Meta-analysis demonstrates improved survival with HIPEC in colorectal cancer with peritoneal metastases, indicating substantial clinical benefits from combined therapy.

Hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery and systemic therapy improves prognosis in colorectal cancer with peritoneal metastases: an updated meta-analysis.

Discussion

Member takes

Implication

Key Points

Cite This Study

Hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery and systemic therapy improves prognosis in colorectal cancer with peritoneal metastases: an updated meta-analysis.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider